Prometheus' spirit: Quality survival in advanced hepatocellular carcinoma after gemcitabine and cisplatin-based chemotherapy

Singapore Medical Journal

Volumn 49, Issue 10, 2008, Pages

  Doval, Dinesh C ^a,b   Pande, S B ^a   Sharma, J B ^a   Pavithran, K ^a   Jena, A ^b   Vaid, A K ^a  

^a RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

^b Department of Magnetic Resonance Imaging ^*

Author keywords

Alpha foetoprotein; Cisplatin; Gemcitabine; Hepatocellular carcinoma; Liver cancer; Liver cirrhosis

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LAMIVUDINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTINUOUS INFUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DEOXYCYTIDINE; FATAL OUTCOME; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; QUALITY OF LIFE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 54949100352     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-17.
2. Bosch F. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer. New York: Churchill Livingstone, 1997: 13-28.
3. National Cancer Registry Programme. Consolidated Report of the Population Based Cancer Registries: Incidence and Distribution of Cancer, 1990-96. Indian Council of Medical Research, New Delhi; 2001 August. Available at: icmr.nic.in/ncrp/ncrp_p/cancer_reg.pdf. Accessed February 7, 2007.
4. National Cancer Institute. Srurveillance Epidemiology and End Results Stat Fact Sheets: Cancer. Available at: www.seer.cancer.gov/statfacts/html/ livibd.html Accessed February 7, 2007.
5. Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 2002; 17:401-5.
6. Guan Z, Wang Y, Maoleekoonpairoj S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 2003; 89:1865-9.
7. Fuchs CS, Clark JW, Ryan DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002; 94:3186-91.
8. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48:783-9.
9. Yang TS, Lin YC, Chen JS, Wang HM, Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000; 89:750-6.
10. Ulrich-Pur H, Kornek GV, Fiebiger W, et al. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology 2001; 60:313-5.
11. Yang TS, Wang CH, Hseih RK, Chen JS, Pung MC, Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: A phase I-II trial. Ann Oncol 2002; 13:1771-1778.
12. Parikh PM, Fuloria J, Babu G, et al. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol 2005; 26:115-8.
13. Taieb J, Bonyhay L, Golli L, et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003; 98:2664-70.
14. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:1898-903.
15. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25 (18S): LBA1.